Table 1.

Baseline Characteristics by Exposure Status

Characteristics	Mean/No. (SD%)		p Value
	Exposed (n = 1,208)	Unexposed (n = 2,416)
TNA type
Focal	679 (56.21)	—
Mixed	157 (13.00)	—
Nonfocal	372 (30.79)	—
Age at matching, y	76.94 (9.25)	76.92 (9.26)	0.96
Sex, female	790 (65.40)	1,580 (65.40)	1.00
Study cohort			0.01
RS-I	875 (72.43)	1,627 (67.34)
RS-II	208 (17.22)	511 (21.15)
RS-III	125 (10.35)	278 (11.51)
Education			0.72
Primary	245 (20.28)	511 (21.15)
Low	534 (44.21)	1,028 (42.55)
Medium	303 (25.08)	604 (25.00)
High	126 (10.43)	273 (11.30)
Smoking status			0.21
Never	469 (38.82)	961 (39.78)
Former	519 (42.96)	970 (40.15)
Current	220 (18.21)	485 (20.07)
BMI, kg/m2	26.94 (3.99)	26.79 (4.01)	0.30
Obesity, ≥30 BMI	232 (19.21)	459 (19.00)	0.92
Systolic, mm Hg	141.06 (21.21)	139.84 (22.26)	0.11
Diastolic, mm Hg	76.19 (11.20)	75.49 (11.73)	0.08
Anti-hypertensive medication use	361 (29.88)	680 (28.15)	0.29
Hypertension	736 (60.93)	1,370 (56.71)	0.02
Total cholesterol, mmol/L	6.48 (1.17)	6.37 (1.26)	0.01
HDL cholesterol, mmol/L	1.37 (0.36)	1.39 (0.37)	0.09
Statin medication use	66 (5.46)	132 (5.46)	1.00
Dyslipidaemia	645 (53.39)	1,204 (49.83)	0.05
Diabetic medication use	44 (3.64)	110 (4.55)	0.23
Diabetes mellitus	86 (7.12)	193 (7.99)	0.39
Atrial fibrillation	40 (3.31)	108 (4.47)	0.11
Anti-thrombotic medication use	46 (3.81)	141 (5.84)	0.01
Follow-up time after matching, y	7.35 (5.97)	7.85 (6.00)	0.02

Abbreviations: BMI = body mass index; HDL = high-density lipoprotein; RS = Rotterdam Study; TNA = transient neurologic attack.

Data were missing for medication use (0.4%), smoking (2.1%), education (2.2%), blood pressure (9.5%), BMI (10.1%), total cholesterol (10.2%), and HDL cholesterol (10.4%).